Patents by Inventor Gijsbertus Franciscus Maria Verheijden
Gijsbertus Franciscus Maria Verheijden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11718681Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.Type: GrantFiled: February 2, 2022Date of Patent: August 8, 2023Assignee: Byondis B.V.Inventors: Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
-
Patent number: 11382982Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: GrantFiled: June 28, 2019Date of Patent: July 12, 2022Assignee: Byondis B.V.Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
-
Publication number: 20220195063Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.Type: ApplicationFiled: February 2, 2022Publication date: June 23, 2022Inventors: Gijsbertus Franciscus Maria VERHEIJDEN, Gerard ROUWENDAL, Roland Jan ARENDS, Timo Kars VAN DEN BERG, Hanke Lottie MATLUNG, Katarina FRANKE
-
Patent number: 11274159Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.Type: GrantFiled: May 15, 2018Date of Patent: March 15, 2022Assignee: Byondis B.V.Inventors: Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
-
Publication number: 20210388107Abstract: The present invention relates to humanized antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the humanized anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with further anti-cancer therapeutics.Type: ApplicationFiled: November 15, 2019Publication date: December 16, 2021Inventor: Gijsbertus Franciscus Maria VERHEIJDEN
-
Publication number: 20210070874Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.Type: ApplicationFiled: May 15, 2018Publication date: March 11, 2021Inventors: Gijsbertus Franciscus Maria VERHEIJDEN, Gerard ROUWENDAL, Roland Jan ARENDS, Timo Kars VAN DEN BERG, Hanke Lottie MATLUNG, Katarina FRANKE
-
Patent number: 10603387Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: GrantFiled: October 31, 2017Date of Patent: March 31, 2020Assignee: Synthon Biopharmaceuticals B.V.Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
-
Publication number: 20190314513Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: ApplicationFiled: June 28, 2019Publication date: October 17, 2019Inventors: Willem DOKTER, Peter Johannes GOEDINGS, Gijsbertus Franciscus Maria VERHEIJDEN, Patrick Henry BEUSKER
-
Publication number: 20180140711Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: ApplicationFiled: October 31, 2017Publication date: May 24, 2018Applicant: Synthon Biopharmaceuticals B.V.Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
-
Publication number: 20170014525Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: ApplicationFiled: July 21, 2016Publication date: January 19, 2017Applicant: Synthon Biopharmaceuticals B.V.Inventors: Willem DOKTER, Peter Johannes GOEDINGS, Gijsbertus Franciscus Maria VERHEIJDEN, Patrick Henry BEUSKER
-
Patent number: 9421278Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: GrantFiled: September 18, 2015Date of Patent: August 23, 2016Assignee: Synthon Biopharmaceuticals B.V.Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
-
Publication number: 20160008486Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: ApplicationFiled: September 18, 2015Publication date: January 14, 2016Applicant: Synthon Biopharmaceuticals B.V.Inventors: Willem DOKTER, Peter Johannes GOEDINGS, Gijsbertus Franciscus Maria VERHEIJDEN, Patrick Henry BEUSKER
-
Patent number: 6964766Abstract: The invention relates to the use of novel peptides in a peptide induced tolerance therapy to prevent autoimmune disorders and in particular their use in treatment of chronic destruction of articular cartilage. The invention furtermore embraces pharmaceutical compositions comprising said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample.Type: GrantFiled: July 16, 1999Date of Patent: November 15, 2005Assignee: Akzo Nobel N.V.Inventors: Gijsbertus Franciscus Maria Verheijden, Anna Maria Helena Boots
-
Publication number: 20020177554Abstract: The invention relates to the use of novel peptides in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases, more specifically arthritis. The invention furthermore embraces pharmaceutical compositions comprising said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample, said T cells being associated with T-cell mediated articular cartilage destruction in autoimmune diseases and test kits to be used in said method.Type: ApplicationFiled: November 13, 2001Publication date: November 28, 2002Applicant: Akzo Nobel N.V.Inventors: Gijsbertus Franciscus Maria Verheijden, Anna Maria Helena Boots
-
Patent number: 6184204Abstract: This invention relates to peptides consisting of 16 to 55 amino acids, said peptides comprising at least one of the amino acid sequences LVCYYTSWS (SEQ ID NO:60), FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), LYPGRRDKQ (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YLKDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO:77) or LDLDDFQGS (SEQ ID NO:78). The peptides can be used in the treatment of T cell-mediated destruction of articular cartilage. Administration of pharmaceutical compositions based on these peptides can be used to induce systemic immunological tolerance to the autoantigens under attack of the autoreactive T-cells.Type: GrantFiled: October 23, 1998Date of Patent: February 6, 2001Assignee: Akzo Nobel N.V.Inventors: Anna Maria Helena Boots, Gijsbertus Franciscus Maria Verheijden
-
Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
Patent number: 5843449Abstract: The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTILAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39, proteins comprising an amino acid sequence which exhibits at least 50% homology with the amino acid sequence YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ ID No: 10) and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases in mammals to induce systemic tolerance of the immune system. The autoantigen HC gp-39, proteins comprising an amino acid sequence which exhibits at least 50% homology with the amino acid sequence YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ ID NO: 10) and said peptides are also suitable to induce arthritis in animals, preferably mice.Type: GrantFiled: April 18, 1996Date of Patent: December 1, 1998Assignee: Akzo Nobel N.V.Inventors: Anna Maria Helena Boots, Gijsbertus Franciscus Maria Verheijden, Ebo Sybren Bos -
Patent number: 5736507Abstract: The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTLAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39 and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases to induce tolerance of the immune system. The autoantigen HC gp-39 and said peptides are also suitable to induce arthritis in non-human animals, preferably mice. The invention furthermore relates to pharmaceutical compositions comprising said autoantigen and/or said peptides, a diagnostic method for the detection of autoreactive T cells in a test sample and test kits to be used in said method.Type: GrantFiled: March 25, 1996Date of Patent: April 7, 1998Assignee: Akzo Nobel N.V.Inventors: Anna Maria Helena Boots, Gijsbertus Franciscus Maria Verheijden